The XALience Trial

Nature et Objective
A Phase 3 study that enrolls participants with chemotherapy‑naïve metastatic castration‑resistant prostate cancer (mCRPC) whose disease has progressed after one prior androgen receptor pathway inhibitor (ARPI). By comparing xaluritamig plus abiraterone against commonly used standard therapies selected by investigators, the trial aims to determine whether targeting KLK2 with xaluritamig can improve survival outcomes in this population. Secondary endpoints will further characterize clinical benefit, including radiographic progression‑free survival, PSA response, objective response rate, and safety.